| Item | Cat. No. | Application | Isotype |
| Anti-NRP1 mAbs [Vesencumab Biosimilar] (MABL-5408) | MABL-5408 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-CRLF2 mAbs [Verekitug Biosimilar] (MABL-5409) | MABL-5409 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-INSR/CD220 mAbs [Verenafusp Biosimilar] (MABL-5410) | MABL-5410 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-HAVCR2/TIM3 mAbs [Verzistobart Biosimilar] (MABL-5411) | MABL-5411 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL3RA/CD123;CD3E mAbs [Vibecotamab Biosimilar] (MABL-5412) | MABL-5412 | ELISA, FACS, Functional assay, in vivo binding | G1;G1, Kappa;Kappa |
| Anti-TIGIT/WUCAM/VSTM3 mAbs [Vibostolimab Biosimilar] (MABL-5413) | MABL-5413 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL1A mAbs [Vilamakitug Biosimilar] (MABL-5414) | MABL-5414 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-CTLA4/CD152 mAbs [Vilastobart Biosimilar] (MABL-5415) | MABL-5415 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL12B/CLMFp40 mAbs [Ustekinumab Biosimilar] (MABL-5386) | MABL-5386 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-TNFRSF9/CD137/4-1BB mAbs [Utomilumab Biosimilar] (MABL-5387) | MABL-5387 | ELISA, FACS, Functional assay, in vivo binding | G2, Lambda |
| Anti-SIGLEC3/CD33/p67 mAbs [Vadastuximab Biosimilar] (MABL-5388) | MABL-5388 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-INSR/CD220 mAbs [Valanafusp Biosimilar] (MABL-5389) | MABL-5389 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL6 mAbs [Vamikibart Biosimilar] (MABL-5390) | MABL-5390 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-STEAP1 mAbs [Vandortuzumab Biosimilar] (MABL-5391) | MABL-5391 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-FZD mAbs [Vantictumab Biosimilar] (MABL-5392) | MABL-5392 | ELISA, FACS, Functional assay, in vivo binding | G2, Lambda |
| Anti-ANGPT2;VEGFA mAbs [Vanucizumab Biosimilar] (MABL-5393) | MABL-5393 | ELISA, FACS, Functional assay, in vivo binding | G1;G1, Lambda;Kappa |
| Anti-VEGFA mAbs [Varisacumab Biosimilar] (MABL-5394) | MABL-5394 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-TNFRSF7/CD27 mAbs [Varlilumab Biosimilar] (MABL-5395) | MABL-5395 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL5 mAbs [Varokibart Biosimilar] (MABL-5396) | MABL-5396 | ELISA, FACS, Functional assay, in vivo binding | G4, Lambda |
| Anti-ITGA2/CD49B mAbs [Vatelizumab Biosimilar] (MABL-5397) | MABL-5397 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
联系我们
Copyright © 2012-2029 西安迈博睿(Mabioway)生物科技有限公司 版权所有
地址:陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层
电话:15339069646 邮箱:info@mabioway.cn
